Heterogeneity Analysis of 18F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting

被引：29

作者：

Budiawan H. ^{[1
,2
]}

Cheon G.J. ^{[1
,3
,4
]}

Im H.-J. ^{[1
]}

Lee S.J. ^{[1
]}

Paeng J.C. ^{[1
]}

Kang K.W. ^{[1
,3
]}

Chung J.-K. ^{[1
]}

Lee D.S. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Seoul National University Hospital, Seoul

[2] Department of Nuclear Medicine, Mochtar Riady Comprehensive Cancer Centre, Siloam Hospitals Semanggi, Jakarta

[3] Cancer Research Institute, Seoul National University, Seoul

[4] Department of Nuclear Medicine, Seoul National University College of Medicine, Jongro-gu, Seoul, 110-744

来源：

Nuclear Medicine and Molecular Imaging | 2013年 / 47卷 / 4期

关键词：

Adenocarcinoma of the lung; Heterogeneity; Lymph node metastasis; Positron emission tomography (PET);

D O I：

10.1007/s13139-013-0216-6

中图分类号：

学科分类号：

摘要：

Purpose: Lymph node (LN) characterization is crucial in determining the stage and treatment decisions in patient with lung cancer. Although 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has a higher diagnostic accuracy in LN characterization than anatomical imaging, differentiating between metastatic and inflammatory LNs is still challenging because both could show high 18F-FDG uptake. The purpose of this study was to assess if the heterogeneity of the 18F-FDG uptake could help in differentiating between inflammatory and metastatic LNs in lung cancer, and to compare with other parameters. Methods: A total of 44 patients with adenocarcinoma of the lung, who underwent preoperative 18F-FDG PET/CT without having any previous treatments and were revealed to have 18F-FDG-avid LNs, were enrolled. There were 52 pathology-proven metastatic lymph nodes in 26 subjects. The pathology-proven metastatic LNs were compared with 42 pathology-proven inflammatory/benign LNs in 18 subjects. The coefficient of variation (CV) was used to assess the heterogeneity of 18F-FDG uptake by dividing the standard deviation of standardized uptake value (SUV) by mean SUV. The volume of interest was manually drawn based on the combined CT images of 18F-FDG PET/CT (no threshold is used). Comparisons were made with the maximum standardized uptake values (SUVmax), visual assessment of 18F-FDG uptake, longest diameter, and maximum Hounsfield units (HUmax). Results: Metastatic lymph nodes tended to have higher CVs than the inflammatory LNs. The mean CV of metastatic LNs (0.30 ± 0.08; range: 0.08-0.55) was higher than that of inflammatory LNs (0.17 + 0.06; range, 0.07-0.32; P < 0.0001). On receiver operating characteristic (ROC) curve analysis, the area under curve was 0.901, and using 0.20 as cut-off value, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 88.5 %, 76.2 %, 82.2 %, 84.3, and 83.0 % respectively. Accuracy of CV was slightly higher than SUVmax and diameter, but significantly higher than visual assessment and HUmax. Conclusions: In patients with adenocarcinoma of the lung having no prior treatments, metastatic LNs showed more heterogeneous 18F-FDG uptake than inflammatory LNs. Measuring the CV of the SUV derived from a manual volume of interest (VOI) can be helpful in determining metastatic LN of adenocarcinoma of the lung. Including diagnostic criteria of CV into the diagnostic approach can increase the accuracy of mediastinal node status. © 2013 Korean Society of Nuclear Medicine.

引用

页码：232 / 241

页数：9

共 39 条

[31]

Scott W.J., Gobar L.S., Terry J.D., Dewan N.A., Sunderland J.J., Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography, J Thorac Cardiovasc Surg, 111, 3, pp. 642-648, (1996)

[32]

Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., Dupont P.J., Bogaert J., Maes A., Et al., Lymph node staging in non small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymphnode stations from 68 patients, J Clin Oncol, 16, pp. 2142-2149, (1998)

[33]

Bryant A.S., Cerfolio R.J., Klemm K.M., Ojha B., Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer, Ann Thorac Surg, 82, pp. 417-423, (2006)

[34]

Kumar A., Dutta R., Kannan U., Kumar R., Khilnani G.C., Gupta S.D., Evaluation of mediastinal lymph nodes using <sup>18</sup> F-FDG PET-CT scan and its histopathologic correlation, Ann Thorac Med, 6, pp. 11-16, (2011)

[35]

Boiselle P.M., Patz E.F., Vining D.J., Weissleder R., Shepard J.A., McLoud T.C., Imaging of mediastinal lymph nodes: CT, MR, and FDG PET, Radiographics, 18, pp. 1061-1069, (1998)

[36]

Silvestri G.A., Gould M.K., Margolis M.L., Tanoue L.T., McCrory D., Toloza E., Et al., Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition), Chest, 132, 3 SUPPL., (2007)

[37]

Shim S.S., Lee K.S., Kim B.T., Chung M.J., Lee E.J., Han J., Et al., Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CTand CT alone for preoperative staging, Radiology, 236, pp. 1011-1019, (2005)

[38]

Kim S.K., Shin J.E., Lee J.H., Peripheral tuberculous lymphadenitis masquerading as metastatic gastric carcinoma on F-18 FDG dual time point PET/CT, Nucl Med Mol Imaging, 46, pp. 316-317, (2012)

[39]

Kim Y.K., Lee K.S., Kim B.T., Choi J.Y., Kim H., Kwon O.J., Et al., Mediastinal nodal staging of non small cell lung cancer using integrated FDG PET/CT in a tuberculosis-endemic country, Cancer, 109, pp. 1068-1077, (2007)

← 1 2 3 4 →